< >

News & Press

Read on to learn more about the latest happenings and events with SEBACIA.

Sebacia EU Real-World Results Demonstrate an Average 79% Improvement in Acne at 6 Months

October 11, 2018 (Duluth, GA) - Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that its real-world, pre-conditioning registry trial in Europe demonstrated that the combination of pre-conditioning followed by Sebacia Microparticles led to an average 79% improvement in facial acne through six months of follow-up.

Read entire press release here


Sebacia Highlights Oral Presentation of EU Real-World Pre-Conditioning Study Results at ASDS Annual Meeting 2018

October 8, 2018 (Duluth, GA) - Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that results from its real-world pre-conditioning study in Europe evaluating Sebacia Microparticles for treatment of facial acne has been accepted for an oral presentation during the American Society for Dermatologic Surgery (ASDS) 2018 Annual Meeting.

Read entire press release here


U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

September 17, 2018 (Duluth, GA) - Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles.

Read entire press release here


Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals, Inc.

May 7, 2018 (Duluth, GA) - Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced a precedential ruling from the U.S. Court of Appeals for the Federal Circuit. The ruling relates to a patent interference proceeding between The General Hospital Corporation (GHC, the owner of certain patents licensed by Sebacia) and Sienna Biopharmaceuticals, Inc. Read more >>

Read entire press release here


Sebacia Announces $36 Million Equity and Debt Financing to Advance Breakthrough In-Office Procedure for Acne

July 25, 2017 (Duluth, GA) - Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced that the company has completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund. Read more >>

Read entire press release here